Agencourt Biosciences uses more modern weapons to win its battles. The company provides genomic services (including DNA and whole genome sequencing) and nucleic acid purification products that help researchers improve the effectiveness of their drug development process. The company has teamed with a handful of international distributors and marketing partners to get its products into users' hands: These partners include Affymetrix and Life Technologies (formerly Invitrogen). Agencourt Biosciences is a subsidiary of Beckman Coulter.

Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule drugs for the treatment of central nervous system disorders. The Company is developing a portfolio consisting of its four product candidates, including pimavanserin, which is in Phase III development for the treatment of Parkinson’s disease psychosis. In addition, the Company has a product candidate in Phase II for chronic pain and a product candidate in Phase I for glaucoma, both in collaboration with Allergan, Inc., and ACP-106 in IND-track development. The Company’s product candidates include Pimavanserin, AGN-XX/YY, AC-262271 and ACP-106. The Company maintains two wholly owned subsidiaries: ACADIA Pharmaceuticals AB based in Malmo, Sweden and ACADIA Pharmaceuticals A/S based in Denmark.

SeraCare Life Sciences, Inc. company was founded in 1984 and is headquartered in Milford, Massachusetts. SeraCare Life Sciences, Inc., a life sciences company, provides products and services to facilitate the discovery, development, and production of human and animal diagnostics, and therapeutics. The company’s portfolio includes diagnostic controls, plasma-derived reagents, and molecular biomarkers, as well as biobanking and contract research services. It operates in two segments, Diagnostic & Biopharmaceutical Products and BioServices. The Diagnostic & Biopharmaceutical Products segment provides controls and panels used for the evaluation and quality control of infectious disease tests in hospitals and clinical labs, blood banks, and in vitro diagnostic (IVD) manufacturing; and reagents and bioprocessing products, including biological materials for use in the research, development, and manufacture of human and animal diagnostics, therapeutics, and vaccines. This segment sells various controls and panels to hospital laboratories, independent clinical laboratories, public health laboratories, blood banks, IVD manufacturers, and government regulatory and research agencies; and reagents and bioprocessing products to diagnostic, pharmaceutical, and biotechnology product developers and manufacturers, as well as to research laboratories affiliated with government, academia, and private foundations.

Galapagos has formed its own archipelago of drugs to treat bone and joint ailments and other diseases. The company uses its proprietary genomic drug-discovery technology to develop medicines to treat rheumatoid arthritis, osteoarthritis, and osteoporosis. Galapagos' pharma services subsidiaryBioFocus DPI offers collaborative drug-discovery services to other pharmaceutical companies. Its drug discovery division works with partners to find, test, and market new drugs. The company's pharmaceutical collaborators include top drugmakers GlaxoSmithKline, Eli Lilly, Merck, and Janssen Pharmaceutica, part of Johnson & Johnson. Galapagos has about 40 projects in its R&D pipeline, most of them through these partnerships.

Cyclacel Pharmaceuticals, Inc. company was founded in 1992 and is headquartered in Berkeley Heights, New Jersey. Cyclacel Pharmaceuticals, Inc., a development-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. Its orally-available drugs in clinical development include Sapacitabine (CYC682), an oral nucleoside analogue, which is in phase II studies for the treatment of hematological malignancies, such as acute myeloid leukemia in the elderly, myelodysplastic syndromes, cutaneous T-cell lymphoma, and lung cancer; Seliciclib (CYC202), a CDK (cyclin dependent kinase) inhibitor, which is in phase II studies for the treatment of lung cancer and nasopharyngeal cancer; and CYC116, an Aurora kinase and VEGFR2 inhibitor that is in phase I studies for patients with solid tumors. The company, through its subsidiary, ALIGN Pharmaceuticals, LLC, markets directly Xclair Cream for radiation dermatitis, as well as Numoisyn Liquid and Numoisyn Lozenges for xerostomia in the United States. It focuses on building a diversified biopharmaceutical business focused in hematology, oncology, and other therapeutic areas based on a portfolio of commercial products and a development pipeline of novel drug candidates.

Chugai Pharmaceutical develops therapies for bone metabolism and blood disorders, cancer, infectious diseases, immune system disorders, and cardiovascular, kidney, and brain diseases. Products include Neutrogin, which treats white blood cell loss related to chemotherapy; Epogin, which treats red blood cell loss caused by chronic kidney failure; Sigmart, an antianginal agent; and Alfarol for osteoporosis. Chugai Pharmaceuticals has foreign operations in Asia, Europe, and North America through subsidiaries and branch locations. Swiss drugs group Roche owns about 60% of Chugai Pharmaceutical.

Bayhill Therapeutics knows that some immune responses are just way out of line. The biopharmaceutical developer is designing vaccines to eliminate problematic immune responses and restore the immune system to its normal state, known as "tolerance." Its product candidate BHT-3009 is being studied in clinical trials as a treatment for multiple sclerosis while its other leading candidate BHT-3021 is in clinical trials for the treatment of type 1 diabetes. The company's pre-clinical candidate, BHT-3034 is being developed as a treatment for myasthenia gravis, an autoimmune disease that causes interruption in the transmission of nerve impulses to muscles.

GTx, Inc. company was founded in 1997 and is headquartered Memphis, Tennessee. GTx, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecules to treat cancer, osteoporosis and bone loss, muscle loss, and other serious medical conditions in the United States. It markets FARESTON tablets for the treatment of metastatic breast cancer in postmenopausal women through wholesale drug distributors. The company develops toremifene citrate, a selective estrogen receptor modulator, which completed pivotal Phase III clinical trial for the prevention of bone fractures and treatment of other estrogen deficiency side effects of androgen deprivation therapy in men with prostate cancer; and for the prevention of prostate cancer in high risk men with precancerous prostate lesions called high grade prostatic intraepithelial neoplasia (PIN), which is in pivotal Phase III clinical trial.GTx it also develops Ostarine, which completed Phase II clinical trial for the treatment of cancer cachexia; GTx-758, an oral luteinizing hormone, which is in Phase I clinical trial for the treatment of advanced prostate cancer; and MK-0773, which is in Phase II clinical trial for the treatment of sarcopenia. In addition, GTx's preclinical pipeline includes GTx-878, an estrogen receptor beta agonist. The company has strategic collaboration with Merck & Co., Inc. to discover and develop selective androgen receptor modulators; license and supply agreement with Orion Corporation to develop and commercialize products containing toremifene; and a collaboration and license agreement with Ipsen Group that provides Ipsen Group the rights to develop and commercialize toremifene in the European territory. It also has collaborations with Hybritech, Inc.; MacroArray Technologies, LLC; and Gen-Probe, Incorporated to develop an accurate blood or urine test to detect high grade PIN.

Formatech provides contract development services for pharmaceutical companies, including cell culture and fermentation, pre-formulation, dosage form, and purification development services. Its dosage forms include liquid, controlled release, tablets, capsules as well as topicals, such as gels, ointments, and creams. It also provides project management services to its contract development customers. The company also offers manufacturing services, such as aseptic fill, finishing, and lyophilization. Formatech's specializations include small molecules, vaccines, and monoclonal antibodies.

Warnex Inc., a life sciences company, provides laboratory services to the pharmaceutical and healthcare sectors in Canada, the United States, and internationally. The company’s Analytical Services division provides quality control services, including chemistry, chromatography, microbiology, method development and validation, and stability studies to pharmaceutical, biotechnology, cosmetics, and veterinary industries. This division offers a range of ICH stability conditions and provides stability management, and revalidates existing methods to ensure compliance with regulatory requirements and performs technology transfers. Its Bioanalytical Services division offers a range of services to the pharmaceutical and biotechnology industries. It specializes in bioavailability and bioequivalence studies, as well as provides services in the areas of research and development, method development, validation, production, and quality assurance.This division helps companies in their drug development programs by carrying out analyses generated in pre-clinical studies and proceeding with evaluation of the drug in human clinical trials. It also provides services to generic drug industry by analyzing physiological fluid samples obtained from studies in humans. The company’s Medical Laboratories division provides specialized laboratory services to the healthcare sector. It offers Prenatest prenatal screening test, which enables pregnant women to find out their risk of carrying a fetus that may be affected by common birth anomalies. This division also provides PRO-DNATM paternity test; genetic testing for human identification, molecular diagnostics, and pharmacogenetics; and testing services in the areas of endocrinology, hematology, infectious diseases, obstetrics/gynecology, and oncology. The company was formerly known as Warnex Pharma, Inc. and changed its name to Warnex Inc. in June 2001. Warnex Inc. was founded in 1996 and is headquartered in Laval, Canada.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.